December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

106.45 +1.19 (+1.13%)
Official Closing Price Updated: 4:10 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
News headline image
The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning ↗
The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes. 
Via Benzinga
News headline image
Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel' ↗
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current... 
Via Benzinga
Topics Government
News headline image
Inflation's Lingering Shadow: Long-Term Expectations Rise Amidst Fed Rate Cuts
The financial markets are currently navigating a perplexing economic landscape where long-term inflation expectations are on the rise, even as the Federal Reserve initiates interest rate cuts. In... 
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
Price Over Earnings Overview: Merck & Co ↗
 
Via Benzinga
News headline image
FDA Clears Merck's One-Minute Cancer Shot ↗
FDA approves Merck's Keytruda Qlex injection for adults with solid tumors. Merck expects it to be available in the U.S. in September. 
Via Benzinga
News headline image
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff ↗
But that doesn't mean Keytruda is safe from the looming patent cliff. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
3 Dirt-Cheap Stocks to Buy Right Now ↗
These stocks share several common denominators, including attractive valuations. 
Via The Motley Fool
Topics Intellectual Property
Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda ↗
Via Stocktwits
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗
Via Stocktwits
News headline image
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill ↗
A high yield is only one part of the story when it comes to picking dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug ↗
Merck received positive Keytruda notes from CHMP regarding its breakthrough cancer treatment with final decisions expected in late 2025. 
Via Benzinga
Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50 ↗
Via Stocktwits
News headline image
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
News headline image
Decoding Merck & Co's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?' ↗
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps,... 
Via Benzinga
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Advancing Cancer Research Brings New Hope for Patients Worldwide
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots ↗
Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices, just days... 
Via Benzinga
News headline image
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
News headline image
Merck & Co. Inc. (NYSE:MRK): A Prime Value Stock with Strong Profitability and Sound Finances ↗
Discover Merck & Co. (MRK), a top value stock with strong profitability, sound financial health, and an attractive valuation. A prime pick for value investors. 
Via Chartmill
News headline image
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
From Daiichi Sankyo
Via Business Wire
News headline image
2 Healthcare Dividend Stocks to Buy and Hold ↗
These drugmakers have competitive yields and have increased their dividends at a good clip. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Merck & Co. Inc. (NYSE:MRK) Excels in Caviar Cruise Quality Stock Screen ↗
Discover Merck & Co. (MRK), a top-tier stock excelling in profitability, high ROIC, strong cash flow, and a robust balance sheet for long-term quality investing. 
Via Chartmill
News headline image
Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs ↗
Pharmaceutical companies are pulling investment from the UK as NHS drug spending falls and pricing disputes worsen. 
Via Benzinga
News headline image
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗
Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial. 
Via Benzinga
News headline image
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.